X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Metal & FMCG, major gainers 
(Wed, 19 Mar 01:30 pm) 
 
Indian share markets continued to trade above the dotted line in the post-noon trading session. Barring IT and auto, all the sectoral indices are trading in the green with metal, FMCG and pharma stocks being the biggest gainers.

BSE-Sensex is up 21 points and NSE-Nifty is trading 15 points up. Both BSE Mid Cap and BSE Small Cap indices are trading up by 0.6%. The rupee is trading at 61.0 to the US dollar.

Most of the large IT stocks are trading in the red with TCS and MPhasis being the biggest losers. As per a leading financial daily, Tech Mahindra is in talks to enter a strategic alliance in Saudi Arabia for offering customer-centric IT services in the banking and financial sectors. The company is also working towards securing projects in New Zealand. The company has operations in all major cities in Australia that will be used as a launch vehicle for providing engineering services to mining businesses in Africa and Indonesia. Tech Mahindra is already providing engineering services to a number of projects in Australia. Apart from that, the company has grown its engineering services to cater to the automobile demand in China and Japan and has expansion plans for Singapore. The company has forecasted 40% annual growth from Association of South East Nations mainly Singapore, Malaysia, Indonesia and Vietnam. Tech Mahindra stock is currently trading down 0.5%.

Majority of the MNC pharma stocks are trading in the red with Novartis and Sanofi being among major losers whereas Merck and Abott are trading in the positive. As per a leading financial daily, Swiss drug company Novartis has been pulled up by the Directorate General of Health Services (DGHS) for allegedly faking documents to seek registration of its vertinary product Tiamulin Hydrogen Fumarate. Drugs Controller General of India (DGCI) has already cancelled the company's import licenses as well as existing registration certificate for the product. DGCI has said that further legal action will be taken in the matter after seeking opinion from the Ministry of Health and Family Welfare. Tiamulin Hydrogen Fumarate is used for respiratory diseases in the poultry industry and is imported by Novartis from its manufacturing facility at Sandoz, Austria. DGHS is also contemplating inspection of the manufacturing site in Austria. Novartis has a total of 26 products registered in India.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Metal & FMCG, major gainers". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE IT


Jul 26, 2017 (Close)

S&P BSE IT 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS